← Back to Search

Neurokinin Antagonist

Tradipitant Low Dose for Motion Sickness

Phase 3

Recruiting

Research Sponsored by Vanda Pharmaceuticals

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 1 day

Awards & highlights

Study Summary

"This trial will study the effectiveness of tradipitant in reducing motion sickness in travelers. It will be a blinded study conducted at multiple centers."

Who is the study for?

This trial is for people aged 18-75 who often get motion sickness when traveling. It's not suitable for those with a BMI over 40, other nausea-causing conditions, or past bad reactions to Neurokinin-1 Receptor blockers.Check my eligibility

What is being tested?

The study tests Tradipitant against a placebo to see if it helps prevent travel-related motion sickness. Participants are randomly assigned to either the drug or placebo group without knowing which one they're getting.See study design

What are the potential side effects?

Tradipitant may cause side effects like headache, drowsiness, dry mouth, and in rare cases allergic reactions. The exact side effects will be monitored throughout the trial.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 1 day

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~1 day

This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 day for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Prevention of vomiting measured by Vomiting Assessment (VA)

Side effects data

From 2021 Phase 1 & 2 trial • 27 Patients • NCT04849559

15%

fatigue

15%

somnolence

diarrhea

restless leg syndrome

depressed mood

peripheral swelling

disturbance in attention

libido decreased

Acne

dizziness postural

headache

100%

80%

60%

40%

20%

Study treatment Arm

Tradipitant

Placebo

Trial Design

3Treatment groups

Experimental Treatment

Placebo Group

Group I: Tradipitant Low DoseExperimental Treatment1 Intervention

Group II: Tradipitant High DoseExperimental Treatment1 Intervention

Group III: PlaceboPlacebo Group1 Intervention

Oral Capsule

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Tradipitant

2016

Completed Phase 3

~1180

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Vanda PharmaceuticalsLead Sponsor

61 Previous Clinical Trials

19,104 Total Patients Enrolled

3 Trials studying Motion Sickness

1,015 Patients Enrolled for Motion Sickness

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Which individuals meet the eligibility criteria for enrollment in this research study?

"Individuals experiencing motion sickness between the ages of 18 and 75 are eligible to participate in this trial, which aims to enroll approximately 300 participants."

Answered by AI

Are individuals still eligible to apply for participation in this ongoing trial?

"Yes, data on clinicaltrials.gov indicates that this research is actively seeking volunteers. The trial was initially listed on 6/1/2023 and last modified on 6/5/2023. Enrollment targets 300 participants from a single site."

Answered by AI

What is the overall count of individuals involved in this research endeavor?

"Affirmative. As per the information available on clinicaltrials.gov, this trial is actively seeking participants. Its initial posting was on June 1st, 2023, and the most recent update occurred on June 5th, 2023. The study plans to enroll a total of 300 individuals at one designated site."

Answered by AI

Can adolescents under the age of 18 participate in this research project?

"Individuals aged 18 to 75 are eligible for enrollment according to the study's inclusion criteria."

Answered by AI

What is the safety profile of Tradipitant in individuals?

"Our team rates the safety of Tradipitant as a 3 on our scale, given that this phase 3 trial has some evidence supporting its efficacy and numerous rounds of data confirming its safety profile."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Motion Serifos: A Study to Investigate the Efficacy of Tradipitant in Participants Affected by Motion Sickness

2023. "Motion Serifos: A Study to Investigate the Efficacy of Tradipitant in Participants Affected by Motion Sickness". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05903924.

All > Motion Sickness